We are very proud to announce that we have closed our first financing round and secured further funding for SRTD. The round was led by High-Tech Gründerfonds (HTGF), alongside renowned business angels who have backed the technology from its inception.
We will use the fresh capital to accelerate the development of our proprietary seRNA technology, which aims to develop highly efficient RNA-based drugs that are active only in diseased cells.
With the closing of this financing round, we are able to confirm the robustness of the platform and to attract further partners.
Our aim is to bring drug candidates for liver cancer into clinical development within the next three years and to make the platform available for other applications.